Vermont embarks on a six-year experiment to redesign health care and how it’s paid for.
San Mateo Medical Center is among hundreds of safety-net hospitals in California and across the country that stand to lose big if the federal government slashes support for Medicaid and insurance exchanges.
Rep. Chris Collins’ enthusiastic investments in Australian biotech company Innate Immunotherapeutics preceded share purchases by the Buffalo Republican’s family members, associates and political donors — raising questions from Washington, D.C., to Sydney.
A drug from Marathon Pharmaceuticals has ignited a firestorm on Capitol Hill and beyond. What makes it different than the $750,000 drug that came before it?
One in four doctors practicing in the U.S. is an international medical doctor. Many foreign-born doctors practice in parts of the country where there are doctor shortages.
A federal judge in Texas last month issued a preliminary injunction barring the government from enforcing a rule allowing insurers to refuse to insure dialysis patients who get premium assistance from charity groups.
After hearing complaints about its high price, Marathon Pharmaceuticals is pausing the launch of an $89,000 drug for a rare disease.
Citing a Kaiser Health News investigation, Senate Judiciary Committee Chairman Chuck Grassley vows to examine the orphan drug program and possible fixes.
The FDA has approved dozens of new cancer medications in recent years, but few offer the benefits that patients seek.
Insurers and care providers say efforts to fix how consumers are notified also raise concerns.
With federal investigators bearing down on his committee, Rep. Tom Price, R-Ga., who is line to be secretary of the Department of Health and Human Services, showed little restraint in investing in health companies.
Luke Whitbeck’s life was saved by a rare disease drug, but it costs $300,000 a year.
With announcements of placements in residencies expected in March, medical education groups and hospitals say they’re unsure how to proceed.
Despite questions about Lupron’s lasting side effects and minimal study into its safety, the FDA sped approval of the drug to market. Years later, some young women are still living with the consequences.
Concerns over U.S. Rep. Tom Price’s answers about stock trades led Senate Democrats to boycott a committee vote that would have moved his nomination to the Senate floor.
A new study, though small, finds extensive damage to commonly used medical scopes that could trap dangerous bacteria. That raises concerns about the potential for more outbreaks.
The device, known as Evzio, administers just enough naloxone to stabilize someone who has overdosed on drugs. But its manufacturer, Kaleo, may be positioning itself to find profits in a dire health care crisis.
The HMO blew two deadlines to supply information required by the state to monitor Medi-Cal managed care plans. Kaiser says it is “taking steps” to resolve the problem.
Rep. Tom Price, up for running HHS under President Trump, helped a company that became a top campaign donor, records show.
The Consumer Financial Protection Bureau reports in a new study that 59 percent of people contacted by a debt collector had outstanding medical bills.